The shares of Geron Corporation (NASDAQ: GERN) rocketed sharply higher on Jan. 23, when the Food and Drug Administration (FDA) granted approval for the world's first clinical trial of human stem cells. Now, GERN has collected an impressive year-to-date gain of 57.8%. However, CEO Thomas Okarma isn't feeling too complacent with his stock's respectable rally. He told Reuters Tuesday, "If this were a normal macro environment, our stock would have tripled with this kind of advance."

No doubt, the FDA's timing could have been better, since Okarma says more money is needed for academic stem cell research -- and demands on federal funding have rarely been greater. "There's no question that there are a lot of big fish in the Washington frying pan these days," commented the CEO. He's calling for the establishment of a presidential commission on stem cell policy to keep the industry on Washington's radar.

Continue reading Geron CEO: Stock 'would have tripled' in normal market conditions

Geron CEO: Stock 'would have tripled' in normal market conditions originally appeared on BloggingStocks on Wed, 11 Feb 2009 14:20:00 EST. Please see our terms for use of feeds.

Continue reading Obama Pick: Buy Osiris Therapeutics (OSIR)

Obama Pick: Buy Osiris Therapeutics (OSIR) originally appeared on BloggingStocks on Wed, 05 Nov 2008 07:15:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• Last November, Google Inc (NASDAQ: GOOG) and 30 partners were said be developing a new type of handset using Android that was expected to revolutionize the industry. The first new phones were expected to be available in this year's second half but are now slated for the fourth quarter the Wall Street Journal reported.
• According to people familiar with the situation, the Wall Street Journal reported that Citigroup Incorporated (NYSE: C) will make sharp cuts in its investment banking division this week.
• The Wall Street Journal reported that Live Nation Inc's (NYSE: LYV) Chairman, Michael Cohl, stepped down down as a director and executive to end the strategy feud with CEO Michael Rapino. over how to pursue the "360 deals" with music superstars.
• The Financial Times reported that there are worries that investment banks will accelerate the pace of their layoffs this summer, after it became known that The Goldman Sachs Group Inc (NYSE: GS) gave pink slips to workers in its investment banking division last week. Goldman is now expected to lay off up to 10% of the workers at the division.

• New Jersey put its $150M center for stem cell research on hold, the Star Ledger reported, eight months after ground was broken on the project.

Newspaper wrap-up: Google's plans for cellphone delayed originally appeared on BloggingStocks on Mon, 23 Jun 2008 08:47:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• Barron's Online's "Weekday Trader" section said that Bankrate Inc (NASDAQ: RATE), Answers Corporation (NASDAQ: ANSW), WebMD Health Corp (NASDAQ: WBMD) and The Knot Inc (NASDAQ: KNOT) may be the next preferred takeover targets for Google Inc (NASDAQ: GOOG) and Microsoft Corporation (NASDAQ: MSFT).
• The Wall Street Journal reported that Brad Tierney is interested in Dow Jones and Company (NYSE: DJ), which in talks with News Corporation's (NYSE: NWS) Rupert Murdoch for a possible $5B sale.
• According to the Wall Street Journal, citing a person close to the deal, Deutsche Telekom (NYSE: DT) will acquire the Orange Netherlands unit of France Telecom for about EUR1.3B, and simultaneously sell Ya.com for EUR320M to them.
• The Financial Times reported that three separate research teams showed the embryonic stem cells can be created by reprogramming some of the genes in adult mice skin cells, without creating an embryo. The news will be well-received by opponents of embryonic stem cell research, but scientists said it is too early to tell if the technique can be used with human cells.

• The Herald Sun reported that a new $237B Chinese state-owned investment fund may be interested in acquiring natural resources company BHP Billiton Limited (NYSE: BHP), according to Bell Potter research chief Peter Quinton.

Newspaper wrap-up 6-07-07: Brad Tierney interested in Dow Jones originally appeared on BloggingStocks on Thu, 07 Jun 2007 09:17:00 EST. Please see our terms for use of feeds.

MAJOR PAPERS:

• Barron's Magazine (subscription required) highlighted a number of possible M&A targets, along with a few stocks it believes to be undervalued:
• M&A is expected to continue in Europe: possible large cap targets include Barclays (NYSE: BCS), Deutsche Telekom (NYSE: DT), Deutsche Bank (NYSE: DB), ABN Amro (NYSE: ABN), Volkswagen (OTC: VLKAY), Koninklljke (NYSE: KPN) and Swisscom (NYSE: SCM); possible small-mid cap targets include Hellenic Telecom (NYSE: OTE).
  
• There may still be upside in shares of Xerox (NYSE: XRX), says James Benson, a partner and securities analyst at Harris Associates.
• Shares of YRC Worldwide (NASDAQ: YRCW) may be undervalued by as much as 50%, says Barron's "Bottom Line," which writes that shares could climb above $60.
• The Wall Street Journal (subscription required) featured an article on Pfizer's new CEO and his strategic plan.
• Pfizer's (NYSE: PFE) new CEO, Jeffrey B. Kindler, is preparing to detail his strategic vision for the company that will likely involve more job cuts.
• Hewlett-Packard (NYSE: HPQ) is claiming a nanotechnology research breakthrough that would bring big benefits in performance.
• According to a Nomura report, Sony Corp (NYSE: SNE) will reach only 75% of its global target for PlayStation 3 sales this fiscal year through March.
• The New York Times had an article highlighting the possibility of New York funding stem cell research.
• New York Governor Eliot Spitzer called for the passage of a $2B 10-year bond initiative for research and development, at least half of which would be set aside to pay for stem cell research.
• Citigroup (NYSE: C) may shorten its name to Citi and drop its umbrella logo.

• The UK Times wrote that Ford (NYSE: F) may have trouble selling its Aston Martin unit after potential buyers found problems in the divisions books while doing due diligence.
• El Pais wrote that Fidel Castro is in "very grave" condition after three failed operations and complications from an intestinal infection known as diverticulitis.

Newspaper wrap-up 1-16-07: Fidel Castro in "very grave" condition originally appeared on BloggingStocks on Tue, 16 Jan 2007 09:25:00 EST. Please see our terms for use of feeds.